Pharmacokinetics of [123I]-Interferon (IFN) Alpha-A
Roberto A. Díez(Universidad de Buenos Aires), E Falcoff, C. Gaudelet(Institut Curie), S. Cornaert(Commissariat à l'Énergie Atomique et aux Énergies Alternatives), B. Perdereau, Catherine Barbaroux(Institut Curie), Thierry Dorval(Centre Hospitalier Universitaire Brugmann), Martine Peter(Inserm), J Wietzerbin(Institut Curie), L. Gauci(Roche (Switzerland)), M. C. Martyré(Institut Curie), P Pouillart(Institut Curie)
Cited by 0
Related Papers
The Phagosome Proteome
|The Journal of Cell Biology|2001|692
RACK1 Competes with HSP90 for Binding to HIF-1α and Is Required for O2-Independent and HSP90 Inhibitor-Induced Degradation of HIF-1α
|Molecular Cell|2007|470
Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma
|Journal of Clinical Oncology|2013|224
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.
|Journal of Clinical Oncology|1998|199